Perceptive Advisors LLC decreased its position in Humana Inc (NYSE:HUM) by 22.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 77,500 shares of the insurance provider’s stock after selling 22,500 shares during the period. Perceptive Advisors LLC owned approximately 0.06% of Humana worth $19,225,000 at the end of the most recent quarter.
Several other hedge funds have also recently made changes to their positions in the company. Cadence Capital Management LLC grew its holdings in shares of Humana by 3.6% in the 3rd quarter. Cadence Capital Management LLC now owns 5,887 shares of the insurance provider’s stock valued at $1,434,000 after buying an additional 205 shares during the period. Daiwa SB Investments Ltd. grew its holdings in shares of Humana by 44.9% in the 4th quarter. Daiwa SB Investments Ltd. now owns 710 shares of the insurance provider’s stock valued at $176,000 after buying an additional 220 shares during the period. HL Financial Services LLC grew its holdings in shares of Humana by 2.1% in the 4th quarter. HL Financial Services LLC now owns 11,205 shares of the insurance provider’s stock valued at $2,780,000 after buying an additional 230 shares during the period. Mackenzie Financial Corp grew its holdings in shares of Humana by 3.6% in the 3rd quarter. Mackenzie Financial Corp now owns 6,642 shares of the insurance provider’s stock valued at $1,618,000 after buying an additional 232 shares during the period. Finally, CIBC Asset Management Inc grew its holdings in shares of Humana by 1.5% in the 4th quarter. CIBC Asset Management Inc now owns 16,996 shares of the insurance provider’s stock valued at $4,216,000 after buying an additional 248 shares during the period. 97.85% of the stock is owned by institutional investors.
Shares of Humana Inc (NYSE:HUM) opened at $272.50 on Monday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.85 and a current ratio of 1.85. Humana Inc has a 52-week low of $203.48 and a 52-week high of $293.35. The company has a market cap of $37,518.98, a PE ratio of 16.34, a price-to-earnings-growth ratio of 1.48 and a beta of 0.95.
The firm also recently declared a quarterly dividend, which will be paid on Friday, April 27th. Shareholders of record on Friday, March 30th will be given a dividend of $0.50 per share. The ex-dividend date is Wednesday, March 28th. This is a boost from Humana’s previous quarterly dividend of $0.40. This represents a $2.00 annualized dividend and a yield of 0.73%. Humana’s payout ratio is 9.59%.
Humana announced that its Board of Directors has approved a stock repurchase program on Thursday, December 14th that allows the company to buyback $3.00 billion in outstanding shares. This buyback authorization allows the insurance provider to repurchase shares of its stock through open market purchases. Shares buyback programs are generally a sign that the company’s board of directors believes its stock is undervalued.
Several equities analysts have recently issued reports on the stock. JPMorgan Chase & Co. boosted their price target on shares of Humana from $253.00 to $271.00 and gave the company a “neutral” rating in a report on Monday, February 12th. Zacks Investment Research lowered shares of Humana from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 19th. Deutsche Bank upped their target price on shares of Humana from $259.00 to $270.00 and gave the stock a “hold” rating in a research note on Friday, February 9th. Jefferies Group raised shares of Humana from a “hold” rating to a “buy” rating and set a $221.00 target price for the company in a research note on Friday, January 12th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and issued a $230.00 target price on shares of Humana in a research note on Tuesday, December 5th. Seven analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $270.47.
In other Humana news, SVP Brian P. Leclaire sold 1,679 shares of the business’s stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $245.97, for a total transaction of $412,983.63. Following the sale, the senior vice president now directly owns 9,888 shares of the company’s stock, valued at approximately $2,432,151.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP Timothy S. Huval sold 1,382 shares of the business’s stock in a transaction dated Tuesday, December 19th. The stock was sold at an average price of $246.04, for a total transaction of $340,027.28. Following the sale, the vice president now directly owns 11,557 shares in the company, valued at $2,843,484.28. The disclosure for this sale can be found here. Insiders have sold a total of 40,579 shares of company stock worth $10,842,942 over the last three months. Insiders own 0.60% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Humana Inc (HUM) Shares Sold by Perceptive Advisors LLC” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/03/12/humana-inc-hum-shares-sold-by-perceptive-advisors-llc.html.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.